ERBB2 and neoplasm: This genomic information is integrated with primary tumor size and nodal status to generates a risk score which translates in points estimations of the 10-year event-free survival in patients undergoing (neo)adjuvant trastuzumab-based chemotherapy, a predictive score accounting for the likelihood of achieving a pathologic complete response (pCR) in case of neoadjuvant trastuzumab-based chemotherapy and a standardized assessment of the ERBB2 mRNA levels in the form of a third score [4].